Cite
HARVARD Citation
Dieci, M. et al. (2019). Impact of 21‐Gene Breast Cancer Assay on Treatment Decision for Patients with T1–T3, N0–N1, Estrogen Receptor‐Positive/Human Epidermal Growth Receptor 2‐Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study. Oncologist. pp. 1424-1431. [Online].